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Abstract
Pituitary adenomas are associated with a variety of clinical manifestations resulting from excessive hormone secretion 
and tumor mass effects, and require a multidisciplinary management approach. This article discusses the treatment 
modalities for the management of patients with a prolactinoma, Cushing's disease and acromegaly, and summarizes 
the options for medical therapy in these patients.
First-line treatment of prolactinomas is pharmacotherapy with dopamine agonists; recent reports of cardiac valve 
abnormalities associated with this class of medication in Parkinson's disease has prompted study in 
hyperprolactinemic populations. Patients with resistance to dopamine agonists may require other treatment.
First-line treatment of Cushing's disease is pituitary surgery by a surgeon with experience in this condition. Current 
medical options for Cushing's disease block adrenal cortisol production, but do not treat the underlying disease. 
Pituitary-directed medical therapies are now being explored. In several small studies, the dopamine agonist 
cabergoline normalized urinary free cortisol in some patients. The multi-receptor targeted somatostatin analogue 
pasireotide (SOM230) shows promise as a pituitary-directed medical therapy in Cushing's disease; further studies will 
determine its efficacy and safety. Radiation therapy, with medical adrenal blockade while awaiting the effects of 
radiation, and bilateral adrenalectomy remain standard treatment options for patients not cured with pituitary surgery.
In patients with acromegaly, surgery remains the first-line treatment option when the tumor is likely to be completely 
resected, or for debulking, especially when the tumor is compressing neurovisual structures. Primary therapy with 
somatostatin analogues has been used in some patients with large extrasellar tumors not amenable to surgical cure, 
patients at high surgical risk and patients who decline surgery. Pegvisomant is indicated in patients who have not 
responded to surgery and other medical therapy, although there are regional differences in when it is prescribed.
In conclusion, the treatment of patients with pituitary adenomas requires a multidisciplinary approach. Dopamine 
agonists are an effective first-line medical therapy in most patients with a prolactinoma, and somatostatin analogues 
can be used as first-line therapy in selected patients with acromegaly. Current medical therapies for Cushing's disease 
primarily focus on adrenal blockade of cortisol production, although pasireotide and cabergoline show promise as 
pituitary-directed medical therapy for Cushing's disease; further long-term evaluation of efficacy and safety is 
important.
Review
Pituitary adenomas are classified according to the charac-
teristic cell type from which the adenoma is derived, and
include prolactinomas, somatotroph, corticotroph,
gonadotroph, thyrotroph and null-cell (nonsecretory)
adenomas. Morbidity associated with pituitary adenomas
results from mass effects of the tumor and/or the effects
of excessive hormone secretion [1]. Estimates of the prev-
alence of pituitary adenomas in the general population
vary greatly. Autopsy and radiological series have sug-
gested that small pituitary tumors may be present in as
many as one in every six people, although these series
include a large proportion of lesions that are not clinically
significant (incidentalomas) [2]. The prevalence of clini-
c a l l y  r e l e v a n t  p i t u i t a r y  a d e n o m a s  i n  a  r e c e n t  B e l g i a n
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study was found to be 1 per 1064 individuals [3], which is
3.5-5 times higher than previously reported estimates of
clinically relevant adenomas; prolactinomas were most
common (66%), followed by null-cell adenomas (14.7%),
somatotroph adenomas (13.2%) and corticotroph ade-
nomas (5.9%) [3].
The aim of this article is to review the treatment
modalities for the management of patients with the three
most frequent hormone-producing tumors: prolactino-
mas, corticotroph adenomas (Cushing's disease) and
somatotroph adenomas (acromegaly), and to summarize
the medical therapy available and under investigation in
these patients.
Management of prolactinomas
Prolactinomas are benign prolactin-producing pituitary
adenomas. In women, the symptoms of hyperprolactine-
mia include infertility, menstrual irregularities, amenor-
rhea, galactorrhea, reduced libido and vaginal dryness,
while in men they include impotence, reduced libido and
infertility. If the tumor is large (a tumor with a diameter
of >1 cm is classified as a macroadenoma), visual field
defects and headache may be the presenting features.
Therefore, patients requiring therapy for prolactinomas
can be divided into two groups: those requiring therapy
for the symptoms of hyperprolactinemia and those
requiring treatment for the effects of tumor burden [4],
a l t h o u g h  s o m e  p a t i e n t s  h a v e  b o t h  h y p e r p r o l a c t i n e m i a
and mass effects, while others may have neither charac-
teristic and may not need treatment.
The goal of treatment for most patients with prolacti-
nomas is restoration of normal prolactin secretion if
there are symptoms directly caused by prolactin excess,
and prevention of hormonal/metabolic consequences (eg
hypogonadism and osteoporosis) [5]. In patients with
large tumors compromising the neurovisual apparatus
(which represents the minority of cases), a decrease in
tumor size is also a goal of treatment.
Current therapeutic options for patients with prolacti-
nomas include observation, medical therapy with dop-
amine agonists (eg bromocriptine, cabergoline),
transsphenoidal or transcranial surgery and conventional
or stereotactic radiotherapy.
Surgery is generally reserved for patients who do not
respond to medical therapy, patients with unstable pitu-
itary hemorrhage or pregnant patients with progressive
tumor enlargement not responding to dopamine agonist
therapy. It may also be used in patients with contraindica-
tions to dopamine agonist use, such as those patients
requiring psychiatric medications that work through the
dopaminergic system. Transsphenoidal surgery is the sur-
gical method of choice, with success rates in centers with
experienced neurosurgeons (based on normalization of
prolactin levels) of approximately 75% in patients with
microprolactinomas and 34% in patients with macropro-
lactinomas [4]. Transcranial surgery is rarely performed,
and is indicated in patients with tumors inaccessible via
the transsphenoidal route. Radiotherapy is typically
reserved for patients with large tumors jeopardizing adja-
cent structures who have not responded to medical or
surgical treatment. Normalization of prolactin levels after
radiotherapy is achieved in about one-third of patients,
and the main complication is radiotherapy-induced
hypopituitarism [4].
Medical treatment of prolactinomas
Prolactin secretion is regulated by the inhibitory signal of
dopamine, acting via the dopamine D2 receptor [4]. Dop-
amine agonists have been used for the treatment of pro-
lactinomas for over 25 years, and are widely considered
the first-line therapy in patients with prolactinomas. Bro-
mocriptine was the first dopamine agonist available for
the treatment of prolactinomas, but others with a longer
half-life, such as pergolide, quinagolide, and cabergoline,
have since become available (although pergolide and qui-
nagolide are not available in the US). The most extensive
experience has been with bromocriptine, although caber-
goline is now widely used. In most patients with prolacti-
nomas, treatment with dopamine agonists normalizes
prolactin levels, restores gonadal function and fertility,
and reduces the size of the tumor. In patients with micro-
prolactinomas, macroprolactinomas or idiopathic hyper-
prolactinemia, normal prolactin secretion was achieved
in 76% of 997 patients treated with bromocriptine, 87% of
98 patients who received pergolide, and 89% of 612 caber-
goline-treated patients [6]. With respect to the efficacy of
this class of medication on tumor reduction in patients
with macroprolactinomas, cabergoline appears to be the
most effective, although there have not been direct com-
parisons. In three separate studies in patients with
macroprolactinomas who received 12-27 months of first-
line therapy with dopamine agonists [7-9], tumor reduc-
tion of more than 50% was seen in 64%, 86% and 96% of
patients treated with bromocriptine, pergolide and caber-
goline, respectively (Table 1).
Although first-line therapy with dopamine agonists is
widely considered the preferred first-line treatment in
patients with prolactinomas, a definitive cure has been
considered possible only with surgery or, rarely, surgery
plus radiotherapy. In patients successfully treated with
dopamine agonists as primary therapy, it has been
unclear if the withdrawal of dopamine agonists is effec-
tive and safe [10]. However, Colao et al have recently
evaluated the long-term effects of dopamine-agonist
withdrawal in patients who received cabergoline as first-
line therapy, and showed that cabergoline can be safely
withdrawn in patients who have achieved normal prolac-
tin levels and have no evidence of residual tumor [11].
Patients in this study had nontumoral hyperprolactine-Biller et al. BMC Endocrine Disorders 2010, 10:10
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mia (n = 25), microprolactinomas (n = 105) or macropro-
lactinomas (n = 75) at baseline, and had been receiving
primary therapy with cabergoline 0.25-3.5 mg/week for
24-75 weeks. Withdrawal of cabergoline was considered
if patients had normal prolactin levels and either no
tumor visible by MRI or at least 50% reduction in tumor
volume. The Kaplan-Meier estimated rate of recurrence
of hyperprolactinemia 5 years after cabergoline with-
drawal was low in patients who had a tumor at baseline
and achieved tumor disappearance, and the recurrence
rate did not differ significantly between patients with
nontumoral hyperprolactinemia (24%), microprolactino-
mas (26.2%) or macroprolactinomas (32.6%). Recurrence
of hyperprolactinemia was higher in patients still pre-
senting small remnant tumors on MRI (41.5% in micro-
and 77.5% in macroprolactinomas). However, in no case
of biochemical recurrence did the tumor regrow or symp-
toms reappear; therapy was reinitiated when prolactin
rose [11]. An additional analysis of estimated rates of
recurrence at 7 years showed remission rates in patients
with small remnant tumors was much lower in patients
with macroprolactinomas than in patients with micro-
prolactinomas (0% vs 20%; P < 0.0001) [4]. Furthermore,
Cox regression analysis determined that tumor diameter
on withdrawal of cabergoline is the major determinant of
recurrent hyperprolactinemia [4]. These results show
that cabergoline can be safely withdrawn in patients with
normalized prolactin levels and no evidence of tumor,
although patients should be closely monitored upon
withdrawal of therapy, particularly those patients with
macroprolactinomas in whom renewed growth of the
tumor may compromise vision. Whether "drug holidays"
should be advised in patients with a substantial decrease
in tumor size, given the recent concern about the effects
of cabergoline on cardiac values, is not yet clear.
Safety of dopamine agonists
The most common adverse effects associated with dop-
amine agonists are nausea and vomiting (~30%), head-
ache (~30%), and dizziness (~25%). Although the type of
adverse events associated with different dopamine ago-
nists are similar, the incidence of these events is lower
with cabergoline and generally less severe than those
associated with bromocriptine or pergolide. Withdrawal
of cabergoline therapy because of adverse events is
reported in less than 3% of patients, compared with about
12% of patients treated with bromocriptine [12].
Of concern are recent reports describing the occur-
rence of valvular insufficiency in patients treated with
cabergoline or pergolide for Parkinson's disease. These
studies showed that the use of cabergoline and pergolide
in patients with Parkinson's disease is associated with an
approximately 5-fold increased risk of newly diagnosed
cardiac valve regurgitation [13,14].
There have been nine recently published studies that
evaluated the prevalence of cardiac valve regurgitation in
a total of 608 patients with prolactinomas who received
long-term cabergoline treatment [15-23]. Eight of the
nine studies showed no evidence of clinically relevant val-
vular regurgitation after prolonged cabergoline treatment
[16-23], although three of the eight studies did show an
increased prevalence of mild tricuspid regurgitation in
cabergoline-treated patients [16,20,23]. However, a sig-
nificant increase in moderate tricuspid regurgitation was
seen with cabergoline treatment compared with controls
in an observational, case-control study by Colao et al.
[15] that compared cardiac parameters in 50 patients
with prolactinomas treated with long-term cabergoline
therapy (median 6.2 years; range 1.1-10.7 years), 50 con-
trol patients and 20 patients with de novo prolactinomas.
Chronic cabergoline treatment did not induce regurgita-
tion of mitral, aortic or pulmonic valves, but an increased
prevalence of moderate tricuspid regurgitation was seen
in treated patients compared with controls (54% vs 18%; P
< 0.0001) and de novo patients (54% vs 0%; P < 0.001). Tri-
cuspid regurgitation was twice as frequent in patients
with a cumulative cabergoline dose of more than 280 mg
than in patients treated with lower cumulative cabergo-
line doses [15].
A recent meta-analysis [24] that pooled results from six
of the studies [15,16,19-22] showed that patients treated
with cabergoline were at increased risk of tricuspid regur-
gitation than control patients, with a prevalence ratio of
1.40 [95% CI 1.17-1.67].
Results from these studies do not provide a definitive
answer, and long-term investigation of this issue will be
important. Some centers suggest echocardiography fol-
Table 1: Effects of first-line therapy with bromocriptine, pergolide or cabergoline on tumor size and prolactin levels in 
patients with macroprolactinomas 
Bromocriptine (n = 27) Pergolide (n = 22) Cabergoline (n = 26)
Baseline prolactin (μg/L) 2260 2938 1013
Normalized prolactin (% of patients) 66 68 100
≥50% tumor reduction (% of patients) 64 86 96
Duration of treatment (months) 12 27 24Biller et al. BMC Endocrine Disorders 2010, 10:10
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low-up studies in patients with prolactinomas treated
with higher doses of cabergoline or other ergot-derived
drugs.
Resistance to dopamine agonists
Although dopamine agonists are an effective treatment
for most patients with prolactinomas, some patients do
not achieve a satisfactory response. Resistance to dop-
amine agonists can be defined as a failure to achieve nor-
malization of prolactin levels or no reduction in tumor
size after 12-24 months of bromocriptine 15 mg/day or
cabergoline 0.5 mg/day [6,25-27]; most cases of resistance
to dopamine agonists can be considered partial resistance
[28]. Approximately 24% and 11% of patients demon-
strate resistance to bromocriptine and cabergoline,
respectively [4]. In patients demonstrating possible resis-
tance to a particular dopamine agonist, increasing the
dose of that agent, as tolerated, may be effective as long as
there is a continuing step-wise decrease in prolactin level
with each step-wise increase in dose. Switching to
another agent may be effective, but patients with resistant
adenomas will usually require surgery, with or without
radiotherapy, if control of a large lesion is needed.
A possible future medical therapy for patients with pro-
lactinomas resistant to dopamine agonists is the multi-
receptor targeted somatostatin analogue pasireotide
(SOM230). In contrast to GH-secreting pituitary ade-
nomas which express predominantly somatostatin recep-
tor subtypes sst2  and sst5, prolactinomas express
primarily sst1 and sst5. Unlike octreotide, which has high
affinity for sst2, pasireotide has a multi-receptor binding
profile, with affinity for sst1,2,3 and sst5. An in vitro study
in prolactinomas cells has demonstrated a stronger inhi-
bition of prolactin with pasireotide than with octreotide,
and that the inhibition of prolactin release was related to
the expression level of sst5 [29]. Studies with pasireotide
have not yet been conducted in patients with prolactino-
mas.
Because prolactinomas express both D2 and sst5 recep-
tors, there is a rationale for the use of chimeric D2/sst5
agonists such as BIM23A760, which has high sst2 and D2
activity and moderate sst5 activity [30,31]. A recent in
vitro study of primary cultures of ten prolactinomas (six
responsive to dopamine agonists and four resistant to
dopamine agonists) showed that BIM 23A760 and caber-
goline produced a similar partial inhibition of prolactin
secretion [32].
Conclusions
First-line treatment of patients with prolactinomas is
pharmacotherapy with dopamine agonists. In some cen-
ters with expert pituitary surgeons, selected patients with
microprolactinomas may be offered surgery based on the
high likelihood of definitive cure, although there are
regional differences in how frequently surgery is advised.
Whether an increased risk for tricuspid regurgitation
associated with cabergoline, especially at higher doses
and with longer treatment periods, should be investigated
carefully. Patients fully responsive to dopamine agonists
who have achieved tumor disappearance can be consid-
ered for withdrawal from the drug with careful follow up.
A small subset of patients with macroprolactinomas that
are less responsive to dopamine agonists may require
more aggressive treatment with surgery and/or radiother-
apy if tumor location or growth rate raises concerns
about compromise of adjacent neurological structures.
Management of Cushing's disease
Cushing's disease is caused by excessive secretion of adre-
nocorticotrophic hormone (ACTH) by a pituitary corti-
cotroph adenoma resulting in enhanced cortisol
secretion from the adrenal glands. Features of hypercorti-
solism include weight gain, severe fatigue and muscle
weakness, high blood pressure, depression, cognitive
impairment, purplish skin striae, hyperpigmentation, loss
of libido, impaired glucose metabolism, hirsutism, acne,
and menstrual disorders [33,34]. Chronic hypercorti-
solism is associated with an increased incidence of sys-
temic arterial hypertension, diabetes mellitus, central
obesity, hyperlipidemia and hypercoagulability [33].
Indeed, 20-50% of the patients with Cushing's disease
have overt diabetes mellitus, whereas impaired glucose
tolerance is present in 30-60% of patients [35]. Cushing's
disease is associated with increased mortality, largely
because of cardiovascular complications, including coro-
nary heart disease, congestive heart disease and cerebro-
vascular events [36].
Treatment goals in Cushing's disease include the rever-
sal of clinical features, the normalization of cortisol levels
with minimal morbidity while preserving pituitary func-
tion, and long-term disease control without recurrence.
In the small number of patients with macroadenomas,
removal of the tumor mass is another treatment goal. The
initial treatment of choice for Cushing's disease is gener-
ally selective pituitary adenomectomy by an experienced,
dedicated pituitary surgeon. Second-line therapy includes
more radical surgery, radiation therapy, including stereot-
actic radiosurgery, medical therapy and bilateral adrena-
lectomy [37,38] Cure rates in patients with Cushing's
disease 10 years after pituitary surgery or radiotherapy
are approximately 77% and 55%, respectively [39].
Although bilateral adrenalectomy is a definitive treat-
ment providing immediate control of hypercortisolism,
patients require lifelong glucocorticoid and mineralocor-
ticoid replacement therapy, and up to 25% of patients
develop Nelson's syndrome or at least regrowth of the
underlying pituitary adenoma [40]. Nelson's syndrome is
the aggressive growth of a pituitary corticotroph ade-
noma after bilateral adrenalectomy, and is associatedBiller et al. BMC Endocrine Disorders 2010, 10:10
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with symptoms such as skin hyperpigmentation, head-
ache and visual impairment, which arise due to the mass
effect of the tumor and increased ACTH secretion [41].
Close monitoring by regular MRI scans and measure-
ment of plasma ACTH levels should be undertaken to
detect the occurrence of corticotroph tumor progression.
Early detection offers the possibility of cure by surgery
(microadenoma) or radiotherapy (invasive adenomas).
Currently, there are no curative medical therapies avail-
able for Cushing's disease. The most commonly used
agents reduce cortisol levels via inhibition of steroidogen-
esis in the adrenal glands and, thus, do not target the
underlying cause of the disease. Adrenal-directed therapy
(eg ketoconazole and metyrapone) is generally used in the
preoperative preparation of patients with severe disease,
or in patients awaiting a response to radiation therapy.
Adrenal-directed therapy
Ketoconazole and metyrapone are the most commonly
used steroidogenesis inhibitors for the treatment of
Cushing's disease. As reviewed by Miller and Crapo [42],
80% of 72 patients with Cushing's disease treated with
ketoconazole 600-1200 mg/day achieved normalization
of urinary free cortisol (UFC) levels. A recent retrospec-
tive analysis of the long-term hormonal effects and toler-
ance of ketoconazole has been conduced in 38 patients
w i t h  C u s h i n g ' s  d i s e a s e ,  w i t h  a  m e a n  f o l l o w - u p  o f  2 3
months. The data demonstrate good tolerability and
effective control, particularly in patients for whom sur-
gery is contraindicated, or delayed during the investiga-
tion of an occult adenoma [43].
In 53 patients with Cushing's disease treated for 1-16
weeks with metyrapone 750-6000 mg/day, 75% achieved
normalization of mean daily plasma cortisol [44]. How-
ever, there is little prospective data on the long-term use
of steroidogenesis inhibitors, and adverse effects limit
their therapeutic use in some patients. Adverse effects
associated with ketoconazole include abnormal liver tests
(15%), gynecomastia (13%), gastrointestinal effects (8%),
edema (6%), and skin rash (2%) [42], whereas adverse
events associated with metyrapone doses >2 g/day
include dizziness and ataxia (15%), nausea (5%), skin rash
(4%), edema (8%) and hirsutism (70%) [44].
Mitotane and etomidate are also sometimes used in the
treatment of Cushing's disease. Mitotane is a derivative of
dichlorodipehyldichlororoethane (DDD) that specifically
inhibits cells of the adrenal cortex. This adrenolytic
action may prove effective in the long term suppression
of hypercortisolism in the majority of patients with
ACTH-dependent Cushing's syndrome [45,46]. Its mech-
anism of action also prevents the risk of escape phenome-
non in response to the ACTH rise that occurs in
Cushing's disease when plasma cortisol is decreased.
However, its onset of action is slow (weeks or months),
and the adverse effects associated with mitotane therapy
(mainly digestive and neurological) require careful moni-
toring of drug levels, and it is routinely used in only a few
centers. Etomidate is a non-opioid anesthetic that also
induces adrenocortical suppression as one of its main
side effects. In situations where rapid control of cortisol
levels is required and oral therapy is problematic, iv eto-
midate therapy may be considered [47-49].
Pituitary-directed therapy
Pituitary-directed medical therapy targets the underlying
cause of the disease, i.e. the ACTH-secreting tumor. A
medical therapy that reverses tumor growth and lowers
ACTH secretion to normal levels, thus normalizing the
amount of cortisol being produced by the adrenal glands,
would be a valuable therapeutic option for the manage-
ment of Cushing's disease. Several pituitary-directed
agents are under evaluation for the treatment of Cush-
ing's disease, including peroxisome proliferator-activated
receptor-gamma (PPAR-γ) agonists such as rosiglitazone
and pioglitazone, dopamine agonists such as bromocrip-
tine and cabergoline, and somatostatin analogues such as
the investigational agent pasireotide.
PPAR-γ is a member of the nuclear receptor super-fam-
ily and functions as a transcription factor. PPAR-γ ligands
have been shown to inhibit cell growth in a number of
tumor types [50], and rosiglitazone has demonstrated in
vitro  antiproliferative and apoptotic effects in corti-
cotroph cells [51]. However, evaluation of normal pitu-
itary tissue and pituitary tumors has shown poor
expression of PPAR-γ receptor in human pituitary tissue,
no detection of a specific abnormality in PPAR-γ expres-
sion in corticotroph tumors, poor immunocytochemical
expression in both normal pituitary and pituitary ade-
nomas, with only weak cytoplasmic staining [52]. In addi-
tion, the antiproliferative effect of rosiglitazone was
shown only at very high doses and these were not blocked
by a specific PPAR-γ antagonist. In two small clinical
studies of rosiglitazone in patients with Cushing's disease,
normalization of UFC levels was achieved in 37.5% of
patients (9/24), whereas in one study of pioglitazone in
five patients with Cushing's disease, no patients achieved
UFC normalization [50,53,54]. More data are required
not only for efficacy, but also to address the long-term
safety of rosiglitazone in these patients, particularly in
light of the recent report that rosiglitazone is associated
with a significant increase in the risk of myocardial
infarction in patients with type 2 diabetes mellitus [55].
The dopamine D2  receptor is expressed in approxi-
mately 75% of corticotroph adenomas [56]. Both bro-
mocriptine and cabergoline have shown in vitro
inhibition of ACTH secretion in corticotroph tumor cells
[56-58], suggesting they may be effective in patients with
Cushing's disease. Miller and Crapo [42] summarized the
results of small studies of patients with Cushing's disease
(n = 1-10) treated with bromocriptine. Of 23 patientsBiller et al. BMC Endocrine Disorders 2010, 10:10
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with Cushing's disease treated with bromocriptine 1.25-
30 mg/day for 3-180 weeks, 42% achieved normalization
of urine or plasma glucocorticoid levels [42], and ACTH
levels decreased by more than 50% in 18% of patients.
Subsequent consecutive studies on the effects of bro-
mocriptine in patients with Cushing's disease did not
confirm relevant efficacy. In a recent study of 20 patients
with persistent Cushing's disease treated with cabergo-
line 1-3 mg/week post surgery, 7 patients (35%) achieved
normalized UFC levels after 3 months of treatment, and
an additional 8 (40%) achieved a ≥25% reduction in UFC
[59]. After 1 year of cabergoline 1-7 mg/week (median
dose 6 mg/week), 50% of patients had normalized UFC,
whereas at 2 years at a median dose of 3.5 mg/week, 40%
of patients had normalized UFC [59]. These promising
results need confirming in larger studies in patients with
Cushing's disease.
Human corticotroph adenomas also express multiple
somatostatin receptor subtypes (sst receptors), with
expression of sst5  predominating [60]. Octreotide has
high affinity for sst2 and moderate affinity for sst5, and is
mostly ineffective in Cushing's disease [61-63]. This lack
of effect in corticotroph cells may be explained by down-
regulation of sst2 receptors [64]. The novel multi-receptor
tageted somatostatin analogue pasireotide has high affin-
ity for sst1, 2, 3 and sst5. The functional activity of pasire-
otide (based on EC50 values) on sst1, sst3 and sst5 is >30-
fold, 11-fold and 158-fold higher, respectively, than that
of octreotide, and is approximately 7-fold lower on sst2
[65]. In preclinical studies, pasireotide has shown signifi-
cant inhibition of basal and stimulated ACTH release in
human ACTH-secreting pituitary adenomas [66,67] and
in AtT-20 murine corticotroph tumor cells [66,68], as
well as significant inhibition of corticotropin-releasing
hormone (CRH)-induced ACTH release in rats (Figure 1)
[69,70].
Results from a short-term, open-label Phase II study of
pasireotide showed that it has the potential for being a
pituitary-targeted medical treatment for Cushing's dis-
ease. Of 29 patients with de novo or persistent Cushing's
disease who received pasireotide 600 μg sc bid for 15
days, UFC levels decreased in 76% of patients and nor-
malized in 17% of patients (Figure 2) [71]. Adverse events
associated with pasireotide were consistent with those
observed with other somatostatin analogues, and
included predominantly mild gastrointestinal events and
mostly transient increases in blood glucose levels. To fur-
ther determine the role of pasireotide in patients with de
novo, persistent or recurrent Cushing's disease, a Phase
III, randomized (between two doses), double-blind, mul-
ticenter trial is ongoing.
The potential for interaction between somatostatin and
dopamine receptors to achieve greater suppression of
ACTH levels is being explored with the development of
chimeric agents. BIM 23A760 is one such agent, with
high sst2 and D2 activity and moderate sst5 activity [30,31].
Observation of a high co-expression of sst5 and D2 in the
majority of human corticotroph adenomas studied sup-
ports the potential for this agent in the treatment of
Cushing's disease; clinical evaluation has not yet been
performed [72].
Other approaches
Mifepristone is the only available glucocorticoid receptor
antagonist. Although clinical data are currently limited in
patients with Cushing's disease, early clinical data have
demonstrated effective treatment of hypercortisolism,
but close monitoring of potentially severe hypokalemia,
hypertension, and clinical signs of adrenal insufficiency is
required [73,74].
Retinoic acid has been shown to be potentially useful in
decreasing corticotroph secretion and proliferation in
rodent models, and more recently in a dog model of
Cushing's disease [75]. However, the effective dose used
in dogs is high and clinical trial results in humans are not
currently available.
Conclusions
Current adrenal-directed medical treatments for Cush-
ing's disease have significant adverse effects and do not
affect the underlying disease or restore normal HPA
dynamics. Pituitary-directed medical therapy would
instead target the underlying cause of the disease and
should be pursued. Although PPAR-γ agonists have dem-
onstrated some efficacy in Cushing's disease, data are
limited and there is currently no routine role for these
agents. A small, short-term study suggests that cabergo-
line may be effective in treating a subset of patients with
Cushing's disease, but more data are required to address
the long-term safety of cabergoline in these patients.
Pasireotide has shown promise as a pituitary-directed
Figure 1 Regulation of CRH-induced secretion of ACTH in rats by 
pasireotide [70]. © 2005 Eur J Endocrinol. Reproduced with permission
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medical therapy in Cushing's disease in a Phase II study.
Long-term efficacy and safety data from Phase III studies
will determine whether pasireotide will have a role in the
treatment of Cushing's disease.
Management of acromegaly
Acromegaly results from chronic hypersecretion of
growth hormone (GH) from a GH-secreting pituitary
adenoma in >90% of patients [76]. GH induces the syn-
thesis of insulin-like growth factor-1 (IGF-1) via hepatic
GH receptors; elevated levels of GH and IGF-1 result in
metabolic dysfunction and somatic growth. The classic
clinical features of acromegaly include acral enlargement,
sweating, headaches and glucose intolerance, and chroni-
cally unrestrained GH hypersecretion can lead to jaw
prognathism, osteoarthritis, frontal bone bossing, diabe-
tes mellitus, hypertension, and respiratory and cardiac
failure [77-80]. Compared with the general population,
patients with acromegaly have 2.4- to 4.8-fold higher risk
of mortality [77,81,82].
The overall goals in the management of acromegaly are
to eliminate morbidity and restore the increased mortal-
ity rate to normal age- and sex-adjusted rates [81-83].
These goals can be achieved using treatments that
remove the tumor mass or reduce and/or control tumor
growth, and restore GH secretion to normal. Reducing
GH levels has been known to reduce mortality rates for
some time [84], and the target GH level has been lowered
progressively as more data are acquired. Currently, the
criteria for cure of acromegaly are GH levels less than 0.4
μg/L after an oral glucose load using a sensitive GH assay,
and IGF-1 levels within the normal age- and sex-adjusted
range [83]. Therapeutic goals in acromegaly are to reduce
and/or stabilize tumor size, control plasma GH and IGF-1
levels (fasting GH levels <2.5 μg/L and IGF-1 levels
within the normal range), preserve pituitary function and
prevent recurrences. Treatment modalities for acromeg-
aly include transsphenoidal surgery, medical therapy and
radiotherapy.
Figure 2 Phase II study of 29 patients with de novo or persistent Cushing's disease receiving pasireotide 600 μg sc bid for 15 days. Mean UFC 
level at baseline and study end (day 15) in each patient (n = 29) are shown. The normal range for UFC is 55-276 nmol/24 h (20-100 μg/24 h); the dashed 
line indicates the upper limit of the normal range. Responding patients (defined as having a UFC level within the normal range at study end) are in-
dicated by the arrows [71]. © 2009 The Endocrine Society. Reproduced with permission.Biller et al. BMC Endocrine Disorders 2010, 10:10
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Pituitary surgery
Transsphenoidal surgery is considered the first-line treat-
ment for the initial management of patients with acro-
megaly, particularly patients with microadenomas who
are likely to be cured after surgical resection [85]. Remis-
sion rates are highest in patients with microadenomas
(75%) and lowest in those with extrasellar macroade-
nomas; the remission rate in patients with a suprasellar
macroadenoma and visual defects is approximately 33%
[86]. When the surgery is performed by an experienced
and pituitary dedicated neurosurgeon, transsphenoidal
surgery has the potential to achieve biochemical cure and
is associated with low mortality (<0.1%) and morbidity
(<2%). However, approximately 70% of patients harbor
macroadenomas; the majority of these patients will have
persistent disease following surgery and will require adju-
vant medical therapy or radiotherapy [86].
Radiotherapy
Conventional external beam radiotherapy has a slow
onset of action, taking up to 15 years for maximal disease
control, causes hypopituitarism in about 50% of patients
and increases cerebrovascular mortality [87]. Stereotactic
radiotherapy administered in a single dose (gamma knife,
proton beam and LINAC) appears to have a faster onset
of action with less hypopituitarism, although long-term
data are limited [88,89]. Radiotherapy for persistent dis-
ease following surgery normalizes IGF-1 levels in up to
59% of patients depending on the series. By about 5 years
after treatment, approximately one-third of patients will
have developed pituitary deficiencies, and this is likely to
increase with longer follow-up [90,91]. Indications for
radiotherapy are post-surgical patients resistant or intol-
erant to medical therapy, and in recurrent, aggressive
tumors.
Medical therapy
The three classes of medical therapy for acromegaly are
based on receptor targets of the GH/IGF-1 axis: pituitary
somatostatin receptor subtypes, pituitary dopamine D2
receptors, and peripheral GH receptors [76,85]. Approxi-
mately 90% of GH-secreting adenomas express sst2 and
sst5; upon stimulation by a sst ligand, these receptors sig-
nal the pituitary to suppress the secretion of GH, result-
ing in decreased hepatic IGF-1 synthesis. More recently,
it has been suggested that a sst ligand may also act
peripherally on the GH/IGF-1 axis by binding to soma-
tostatin receptors on peripheral organs, such as hepato-
cytes in the liver, to inhibit the secretion of IGF-1 [92].
Do pam i ne a g onis ts bin d t o pit u itary  D 2 receptors, and
although the exact mechanism by which dopamine ago-
nists inhibit GH secretion from pituitary adenoma cells is
not known, it is thought they act by decreasing the intrac-
ellular calcium concentration [85,93]. Thirdly, antago-
nism of peripheral GH receptors blocks the action of GH
at the receptor which inhibits the synthesis of IGF-1 and
lowers serum levels; GH levels remain elevated [94], but
are blocked by the medication.
Somatostatin analogues are the first choice for the
medical treatment of acromegaly in most patients. Oct-
reotide and lanreotide are synthetic analogues of soma-
tostatin that selectively bind to sst2 and to a lesser extent
sst5 (Table 2), and have more prolonged pharmacological
actions than the endogenous hormone.
Depot formulations of these analogues, octreotide
LAR, lanreotide SR and lanreotide Autogel, have
improved the clinical application of these compounds;
octreotide LAR and lanreotide Autogel are administered
once every 28 days, whereas lanreotide SR is adminis-
tered once every 7-14 days.
Up to 75% of patients treated for 12-36 months with
octreotide LAR as adjuvant therapy achieve control of
GH levels and/or IGF-1 levels [95]. In a meta-analysis by
Freda  et al, 57% and 67% of patients treated with oct-
reotide LAR as adjuvant therapy achieved GH levels <2.5
μg/L and IGF-1 normalization, respectively. In patients
treated with lanreotide SR as adjuvant therapy, GH levels
<2.5 μg/L and IGF-1 normalization was achieved in 48%
and 47% of patients, respectively [96]. There are fewer
data available for lanreotide Autogel, but it has been
shown to be as least effective as lanreotide SR when used
as adjuvant therapy in patients with acromegaly [97].
First-line therapy with somatostatin analogues in
patients with previously untreated acromegaly has
received considerable attention since Newman et al
showed that primary therapy with subcutaneous oct-
reotide was as effective as adjuvant therapy with subcuta-
neous octreotide (following surgery or radiotherapy) at
controlling GH and IGF-1 levels in patients with large or
invasive tumors without visual or neurological distur-
Table 2: Somatostatin receptor subtype (sst) binding affinities of somatostatin and analogues in nmol/L 
sst1 sst2 sst3 sst4 sst5
Somatostatin-14 0.1-2.3 0.2-1.3 0.3-1.6 0.3-1.8 0.2-0.9
Octreotide 280->1000 0.4-2.1 4.4-34.5 >1000 5.6-32
Lanreotide 180->1000 0.5-1.8 14-107 66->1000 0.6-17
Pasireotide 9.3 1.0 1.5 >1000 0.16Biller et al. BMC Endocrine Disorders 2010, 10:10
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bances [98]. Most studies of first-line therapy of acromeg-
aly with somatostatin analogues evaluated octreotide
LAR, and recent studies have demonstrated that first-line
therapy with octreotide LAR reduces GH and IGF-1 lev-
els to a similar or greater extent than when administered
after surgery and/or radiotherapy (Table 3) [99-106], and
reduces pituitary tumor size (usually defined as a 10-25%
reduction) in most patients (Table 3 and Figure 3) [99-
107]. Indeed, results from a prospective, long-term study
(up to 9 years) in 67 patients with de novo acromegaly
showed that 68.7% and 70.1% of patients treated with oct-
reotide LAR as first-line therapy achieved GH levels <2.5
μg/L and normal IGF-1 levels, respectively, and tumor
volume decreased by >25% in 82% of patients [104].
In order to achieve the reversal of comorbidities and to
decrease premature mortality in patients with acromeg-
aly, long-term biochemical control is necessary. Recent
studies have demonstrated the importance of regularly
monitoring of GH and IGF-1 levels during treatment with
somatostatin analogues, and that dose escalation should
be performed if optimal control (GH <2.5 μg/L and nor-
mal IGF-1 levels) has not been achieved. In the recent
study by Colao et al [103], in which 56 newly diagnosed
patients received octreotide LAR as first-line therapy for
24 months, after 3 months of treatment with octreotide
LAR 20 mg/month the dose was increased to 30 mg/
month in patients with inadequate control of GH (GH
>2.5 μg/L) and/or IGF-1 levels. After a further 9 months,
the dose was increased to 40 mg/month in those patients
who still remained inadequately controlled. At the end of
the 24-month study, 80% of patients had achieved GH
and IGF-1 control, and mean GH and IGF-1 levels had
decreased by 93% and 63%, respectively. Moreover, 85%
of the patients had achieved a tumor volume reduction of
>25% (Table 3) [103].
Suitable candidates for first-line therapy with soma-
tostatin analogues might include patients with no risk of
visual impairment from the tumor, patients with tumors
unlikely to be controlled by surgery (eg lateral cavernous
sinus invasion), patients who are at high surgical risk, and
patients who decline surgery [83].
Pasireotide is also being evaluated in patients with
acromegaly [69,108,109]. Based on the differences in
binding affinity and functional activity of pasireotide and
octreotide, it can be speculated that in cells and tissues
that express sst receptors other than sst2, pasireotide may
Figure 3 Effect of somatostatin analogues on pituitary tumor size 
in patients with acromegaly, showing the percentage of patients 
with >10% tumor volume reduction after adjuvant or first-line 
therapy [107]. © 2005 The Endocrine Society. Reproduced with permis-
sion.
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Table 3: Summary of results from studies of first-line therapy with octreotide LAR in patients with acromegaly
Reference No of pts Duration of 
treatment
Patients meeting 
criterion for GH 
control (%)
Patients with 
IGF-1 
normalization 
(%)
Mean tumor 
shrinkage (%)
% of patients with 
significant tumor 
shrinkage (definition of 
significant)
Colao et al 2001 [101] 15 12-24 months 73 53 53 80 (>20%)
Amato et al 2002 [99] 8 24 months 50 50 34.8 100 (>10%)
Ayuk et al 2004 [100] 25 48 weeks 62 64 NR NR
Jallad et al 2005 [105] 28 6-24 months NR 43 NR 76 (>25%)
Colao et al 2006 [102] 34 6 months 61 45.5 54 (median) 74 (>30%)
Cozzi et al 2006 [104] 67 6-108 months 69 70 62 82 (>25%)
Mercado et al 2007 [106] 68 48 weeks 44 34 39 75 (>20%)
Colao et al 2007 [103] 56 24 months 86 84 68 NR
Colao et al 2008 [127] 67 12 months 52 58 49 85 (>25%)
Colao et al 2008 [128] 40 48 weeks NR NR 35 73 (>20%)
NR = not reportedBiller et al. BMC Endocrine Disorders 2010, 10:10
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have a stronger inhibitory effect on hormone secretion
than octreotide [69]. Moreover, the multi-receptor bind-
ing profile of pasireotide suggests that it may be effective
in patients with acromegaly resistant or refractory to oct-
reotide. Results from a Phase II study show that pasire-
otide effectively controls GH and IGF-1 levels in patients
with de novo or persistent/recurrent acromegaly, and sig-
nificantly reduces pituitary tumor volume [69,110,111].
Results from an ongoing randomized, double-blind Phase
III study comparing the efficacy of a long-acting release
formulation of pasireotide with that of octreotide LAR in
patients with acromegaly will help determine whether
this agent is effective and safe.
Somatostatin analogues are well tolerated in most
patients and treatment discontinuations due to adverse
events are rare. The most common adverse events associ-
ated with somatostatin analogues are injection-site dis-
comfort and erythema, gastrointestinal disturbances such
as diarrhea, abdominal pain, flatulence, steatorrhea, nau-
sea and vomiting, biliary sludge or gallstones, and tran-
sient hyperglycemia. However, most adverse events are
mild or moderate and are transient [95].
Dopamine agonists were the first effective medical
therapy for acromegaly, but have since been superseded
by somatostatin analogues. Dopamine agonists can con-
trol GH and/or IGF-1 levels in 15-40% of patients with
acromegaly [112,113]. However, high doses are required
and dopamine agonists are associated with nausea, pos-
tural hypotension and possible risk of cardiac valve regur-
gitation [13,14]. The addition of cabergoline to
somatostatin analogue therapy may improve response in
patients who otherwise are not fully controlled by maxi-
mal doses of somatostatin analogues, and in patients with
adenomas co-secreting GH and prolactin [114]. The
potential for dual somatostatin/dopamine activity in the
treatment of patients with acromegaly will be addressed
in studies of the chimeric dopamine/somatostatin recep-
tor agonist BIM-23A760. In normal cynomolgus mon-
keys, BIM-23A760 has been seen to produce potent dose-
related GH suppression, with no effect on circulating
insulin or glucose levels [115].
Pegvisomant is the only GH receptor antagonist avail-
able; it has been shown in clinical trials to normalize IGF-
1 levels in up to 97% of patients, and can improve comor-
bidities such as insulin resistance [94,116-118]. Further-
more, because the efficacy of pegvisomant is not
dependent on tumor somatostatin receptor expression,
pegvisomant effectively inhibits IGF-1 secretion in
patients who are non- or partial responders to somatosta-
tin analogues. GH secretion is not inhibited during pegvi-
somant therapy and pegvisomant does not treat the
tumor, necessitating regular monitoring for pituitary
tumor growth [116-118]. Recent studies suggest that the
addition of pegvisomant to somatostatin analogue ther-
apy may increase the proportion of patients achieving
normal IGF-1 levels, offset the lack of effect of pegviso-
mant on tumor growth, and improve the quality of life of
patients with adequately controlled disease during soma-
tostatin analogue monotherapy [119-121]. Although
pegvisomant therapy is generally well tolerated, it is asso-
ciated with elevated liver enzymes in a small proportion
of patients and liver transaminase levels need to be moni-
tored during therapy. Although rare, lipodystrophy at the
site of injection has been reported during pegvisomant
therapy, suggesting patients should undergo examination
of the injection site [122]. Additional studies are required
to ascertain the long-term safety of pegvisomant.
Conclusions
Surgery remains the first-line treatment option in
patients with GH-secreting tumors. Somatostatin ana-
logues may be used as first-line therapy in selected
patients with large extrasellar tumors not amenable to
surgical cure, in patients at high surgical risk, and in
patients who decline surgery. Adjuvant therapy with
somatostatin analogues is indicated after non-curative
surgery and after radiotherapy when GH levels remain
elevated. Pegvisomant is typically used in patients who
have not responded to surgery and/or radiotherapy and
other medical therapies, or in patients in whom glucose
control may play a role in the selection of medication
(depending on local approval), because it can improve
insulin resistance. Dopamine agonists can be considered
in patients with a prolactin co-secreting adenoma.
Summary
▪ First-line treatment of patients with prolactinomas is
pharmacotherapy with dopamine agonists; surgery is
indicated in the few patients with resistant adenomas
who have compromise of the neurovisual apparatus or
other adjacent neurological structures, or with contrain-
dications to dopamine agonist use. Radiotherapy is indi-
cated for selected patients, such as those who have not
responded to medical or surgical treatment.
▪ First-line treatment of patients with Cushing's disease
is pituitary surgery by an expert pituitary surgeon.
Results from early, small studies evaluating pituitary-
directed medical therapy, such as pasireotide and caber-
goline, are encouraging, but further study is needed.
Additional approaches include radiation therapy and
adrenal-directed therapy, as well as bilateral laparoscopic
adrenalectomy for immediate remission of hypercorti-
solemia when other approaches have failed and patients
remain intolerant or incompletely treated.
▪ First-line treatment of patients with acromegaly is
pituitary surgery when the outcome of the surgery is
likely to be complete resection of the pituitary adenoma,
or to debulk significant tumor, particularly if neurologicalBiller et al. BMC Endocrine Disorders 2010, 10:10
http://www.biomedcentral.com/1472-6823/10/10
Page 11 of 14
structures are in jeopardy. Somatostatin analogues may
be used as first -line therapy for acromegaly in selected
patients with large extrasellar tumors not amenable to
surgical cure, frail patients, patients at high surgical risk,
and patients who decline surgery.
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